Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?

Is REGN a bully banal to buy? We came crossed a bullish thesis connected Regeneron Pharmaceuticals, Inc. connected Ocular Capital’s Substack. In this article, we volition summarize the bulls’ thesis connected REGN. Regeneron Pharmaceuticals, Inc.'s stock was trading astatine $774.66 arsenic of March 11th. REGN’s trailing and guardant P/E were 18.68 and 18.05, respectively according to Yahoo Finance.

Nestor Rizhniak/Shutterstock.com

Regeneron Pharmaceuticals, Inc. (REGN) stands retired arsenic a almighty innovation motor wrong the biopharmaceutical industry, driven by beardown foundational subject and a proven quality to commercialize breakthrough therapies. At the center of its maturation communicative is Dupixent, a blockbuster cause that has rapidly go 1 of the astir palmy treatments successful modern medicine. Originally approved for atopic dermatitis, Dupixent has expanded into additional indications specified arsenic asthma and different inflammatory diseases, demonstrating exceptional efficacy and a widening diligent base.

The cause is wide expected to go 1 of the best-selling pharmaceuticals of each time, generating important and recurring gross for the company. This almighty currency travel allows Regeneron to reinvest heavy into probe and development, creating a self-sustaining rhythm of innovation. Rather than relying on a azygous product, Regeneron Pharmaceuticals, Inc. has built a wide and promising pipeline spanning oncology, cardiovascular medicine, and uncommon diseases. The company’s proprietary platforms and scientific expertise enable it to continuously identify and make caller therapies, reinforcing its semipermanent competitory positioning successful the biotech sector.

This strategy transforms the occurrence of Dupixent into a backing motor for aboriginal breakthroughs, allowing the institution to prosecute aggregate high-value opportunities simultaneously. As a result, Regeneron Pharmaceuticals, Inc. is not merely benefiting from a impermanent blockbuster cause but has established a durable innovation level susceptible of delivering sustained growth. With a highly profitable flagship therapy and a heavy pipeline supported by beardown technological infrastructure, the institution is positioned to stay a large unit successful the planetary biopharmaceutical marketplace for years to come.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the commercialized imaginable of Casgevy for sickle compartment disease, improving security reimbursement, and a promising gene-editing pipeline. CRSP’s banal terms has appreciated by astir 21.86% since our coverage. Ocular Capital shares a akin presumption but emphasizes connected Regeneron Pharmaceuticals, Inc. (REGN)’s Dupixent-driven maturation and its self-funding innovation pipeline.